Pharmaceutical - Markets & Marketing, Anti-virals

Filter

Popular Filters

1 to 25 of 45 results

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

New treatments to boost hepatitis C market to $19.2 billion by 2016

New treatments to boost hepatitis C market to $19.2 billion by 2016

24-06-2014

The launch of interferon-free regimens is expected to boost the hepatitis C market from $2.9 billion…

Anti-viralsAntiviralsBusiness FinanceCytokinesDatamonitorGilead SciencesGlobalMajorMarkets & MarketingPharmaceuticalSovaldi

Arrival of new hepatitis C therapies will increase the drug-treated population in China

Arrival of new hepatitis C therapies will increase the drug-treated population in China

19-06-2014

China’s market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated…

Anti-viralsasunaprevirBristol-Myers SquibbChinadanoprevirGilead SciencesJanssenMarkets & MarketingOlysioPharmaceuticalRocheSovaldi

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

02-05-2014

Having achieved the biggest drug launch to date by generating an astonishing $2.3 billion in its first…

AbbVieAnti-viralsBayerBristol-Myers SquibbCardio-vascularDiabetesGilead SciencesHumiraJanuviaLantusMarkets & MarketingMerck & ConivolumabPharmaceuticalSanofiSovaldiXarelto

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Global Fund taps pharmaceutical expertise in China

02-04-2014

The Global Fund is deepening its partnership with China by tapping the expertise of Chinese pharmaceutical…

Anti-viralsAntibiotics and Infectious diseasesChinaGlobalMarkets & MarketingPharmaceuticalProductionRegulation

High incidence and inadequate treatments boost prospects of HIV, Chagas, Dengue and influenza H1N1 drugs in Latin America

High incidence and inadequate treatments boost prospects of HIV, Chagas, Dengue and influenza H1N1 drugs in Latin America

17-03-2014

The high incidence of human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well…

Anti-viralsAntibiotics and Infectious diseasesGenericsMarkets & MarketingPharmaceuticalSouth America

Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir

21-02-2014

US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

Modest growth expected for hepatitis B vaccine market

Modest growth expected for hepatitis B vaccine market

12-02-2014

The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming…

Anti-viralsDynavax TechnologiesHeplisavHexyonMarkets & MarketingPharmaceuticalSanofiSanofi Pasteur MSDVaccines

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

Brazil to produce atazanavir to supply SUS demand; strong pharma growth forecast for 2014

15-01-2014

Following the Official Gazette market application filling for the drug atazanavir sulfate, an HIV protease…

Anti-viralsatazanavirBrazilBristol-Myers SquibbFiocruzGenericsMarkets & MarketingPharmaceuticalProductionSouth America

Brazil National Health System coverage of and access to HIV drugs

Brazil National Health System coverage of and access to HIV drugs

27-12-2013

Brazil’s National Health System (SUS) currently provides coverage for 22 drugs that are distributed…

AbbVieAnti-viralsAtriplaBrazilEvipleraGilead SciencesGlaxoSmithKlineHealthcareKaletra TabletsMarkets & MarketingPharmaceuticalSouth AmericaTriovirTruvadaViread

IFPMA and the Global Fund collaborate to help protect patients from fake medicines

05-12-2013

The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

Influenza products market to grow at a CAGR of 8% through 2018

14-11-2013

The influenza products market, including vaccines, antivirals and diagnostic products, has been forecast…

Anti-viralsGlobalMarkets & MarketingPharmaceutical

Roche strikes deal with Medicines Patent Pool on medicines access

05-08-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement with the Medicines Patent Pool, a Geneva,…

Anti-viralsMarkets & MarketingPharmaceuticalPricingRocheValcyte

US and European gastroenterologist's views on hepatitis C treatments

02-05-2013

Gastroenterologists in the USA and Europe by health care advisory firm Decision Resources agree that…

Anti-viralsBiotechnologyEuropeMarkets & MarketingNorth AmericaPharmaceuticalResearch

Combination drugs will drive Europe's hepatitis B and C therapeutics markets, says F&S

30-04-2013

The limited efficacy and negative side effects associated with current therapeutics for hepatitis B and…

Anti-viralsEuropeMarkets & MarketingPharmaceuticalResearch

New drug candidates hold promise for European HIV drugs market, says F&S

16-04-2013

The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination…

Anti-viralsEuropeMarkets & MarketingPharmaceutical

Roche teams up with Ascletis on hep C treatments for China

15-04-2013

Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

European HIV diagnostics manufacturers need to target large, undiagnosed HIV population

19-02-2013

Over 32% of HIV+ people in Europe remain undiagnosed. This large untapped pool and the development of…

Anti-viralsEuropeMarkets & MarketingPharmaceutical

Cytomegalovirus infections market completely controlled by Roche's Valcyte

05-02-2013

The global cytomegalovirus (CMV) infections market has been forecast to increase at a compound annual…

Anti-viralsletermovirMarkets & MarketingMerck & CoPharmaceuticalRocheValcyte

Japan's seasonal flu vaccines market analysis

16-01-2013

The Japanese influenza vaccine market is valued at around $702 million in 2012, according to a new report…

Anti-viralsAsia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalSanofiVaccines

Need for global policy innovation to tackle the "Silent Pandemic" that is hepatitis C, says EIU report

16-01-2013

There is an urgent need for countries around the world to develop strategies to tackle head-on the growing…

Anti-viralsBiotechnologyGlobalHealthcareMarkets & MarketingPharmaceutical

1 to 25 of 45 results

Back to top